Resultaten van dit onderzoek US-Army volgt ook nog medio juli 2014!
Ischaemia Reperfusion Injury
Ischaemia Reperfusion Injury (IRI) is a complication arising from lack of oxygen due to an interruption of the blood supply
(ischaemia) and subsequent resolution (reperfusion) resulting in tissue damage. This can occur in a transplanted organ, in
the brain as a result of stroke, and in the heart in the case of myocardial infarction ('heart attack'). Ruconest® has been
shown in various pre-clinical models that it can limit the extent of the IRI.
In 2013, we received additional positive data on the use of Ruconest® to decrease the damage caused by IRI. Dr. Luis
Fernandez and his colleagues from the University of Wisconsin presented data from a primate model showing that
Ruconest® could significantly reduce the complication of delayed graft function when given to donors prior to kidney
transplantation. In addition, Dr. Thierry Hauet and colleagues from the University of Poitiers showed that Ruconest® was
also effective in reducing IRI in a pig model when given to recipient animals prior to kidney transplantation. The results from
this study will be presented at the World Transplant Congress in San Francisco in July 2014.
11
Management report continued
In addition to the work in transplantation, Pharming is continuing its collaboration with the US Army Institute of Surgical
Research (US Army) to evaluate the potential for Ruconest® to reduce IRI in haemorrhagic shock, a serious complication of
civilian and military traumatic injuries. Further results are expected this year and we are exploring options, together with the
US Army, on how to move the development of Ruconest® forward in this important indication. Together, the data provide
strong support to evaluate Ruconest® in clinical conditions with IRI, such as transplantation and acute myocardial infarction.
During the course of 2014, we anticipate refining our development plans to study Ruconest® in these indications with significant unmet medical need.